Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 10, 2003, Pages 1298-1299

  Mitchison, Denis Anthony ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PLASMA PROTEIN; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL METABOLISM; BACTERIUM CULTURE; CELL DIVISION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG PROTEIN BINDING; EDITORIAL; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFLAMMATORY CELL; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MALE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 0037952797     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2302005     Document Type: Editorial

References (13)

1. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N, Hodge T, and the Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-1347.
2. Tam CM, Chan SL, Kam KM, Sim E, Staples D, Sole KM, Al-Ghusein H, Mitchison DA. Rifapentine and isoniazid in the continuation phase of a 6-month regimen - nterim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000;4:262-267.
3. Jindani A, Doré CJ, Mitchison DA. The bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-1354.
4. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
5. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilising activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123:367-371.
6. Wilson M, DeRisi J, Kristensen H-H, Imboden P, Rane S, Brown PO, Schoolnik GK. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridisation. Proc Natl Acad Sci USA 1999;96:12833-12838.
7. Mitchison DA. Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998;2:612-615.
8. Canetti G. Tuberculous lesions and immunity: nature of the tuberculous lesion. In: The tubercle bacillus in the pulmonary lesion of man: histobacteriology and its bearing on the therapy of pulmonary tuberculosis. New York: Springer; 1955. p. 145-150.
9. Dhillon J, Mitchison DA. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Repir Dis 1992;145:212-214.
10. Dickinson JM, Mitchison DA. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 1987;68:113-118.
11. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium. Lancet 1999;353:1843-1847.
12. Aber VR, Nunn AJ. Factors affecting relapse following short-coursē chemotherapy. Bull Int Union Tuberc 1978;53:260-264.
13. Lounis B, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001;45:3482-3486.